One of the strands currently explored is medicinal Cannabis. In a review carried out in the Pubmed, Cochrane, Biblioteca Virtual em Sa\u00fade [Virtual Health Library] (BVS) and Scielo, <\/span><\/span>Sousa and Marques<\/span><\/span><\/a> databases, they conclude that medicinal Cannabis is a promising therapy to aid in the treatment of Alzheimer\u2019s Disease, as it has few side effects and act directly on the main pathophysiological mechanisms of the disease<\/strong> (regulation of neurotransmitters, formation and deposition of \u03b2 amyloid plaques, toxicity and neuronal death). The work was presented at the VI International Congress on Human Aging, in 2019.<\/p>\n \u00a0<\/p>\n Read on: Findings on the use of Cannabis in the Alzheimer\u2019s Disease: a literature review<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n In 2016, a <\/span><\/span>study<\/span><\/span><\/a> was carried out with 11 participants with AD, all with behavioral and psychological symptoms related to dementia. Patients were treated with Cannabis oil for 4 weeks and the results were promising: a significant reduction in the Clinical Global Impression score, less caregiver stress and improvement in neuropsychological domains<\/strong> such as delusions, insomnia, apathy and irritability were observed. Apparently, this occurred due to the activation of the <\/span><\/span>Endocannabinoid System<\/span><\/span><\/a> and, consequently, to the reduction of neuronal death induced by deposition of \u03b2 amyloid plaques.<\/p>\n \u00a0<\/p>\n Check here the study <\/strong><\/span><\/span>Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n Another 2014 <\/span><\/span>study<\/span><\/span><\/a> of Alzheimer\u2019s and medical Cannabis in mice, improvement in symptoms of memory loss, social recognition and learning<\/strong>was seen in the animals. Alzheimer\u2019s mice were 1 year old and were treated with 50 mg\/kg\/day of CDB for 3 weeks. The reduction in symptoms was accompanied by a decrease in beta amyloid protein deposits in the hippocampus of the animals.\u00a0<\/p>\n \u00a0<\/p>\n See <\/strong><\/span><\/span>Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n In another 2020 <\/span><\/span>study<\/span><\/span><\/a> of Alzheimer\u2019s and medical Cannabis in mice, improvement in symptoms of memory loss, social recognition and learning<\/strong> was seen in the animals. Alzheimer\u2019s mice were 1 year old and were treated with 50 mg\/kg\/day of CDB for 3 weeks. The reduction in symptoms was accompanied by a decrease in beta amyloid protein deposits in the hippocampus of the animals.<\/p>\n \u00a0<\/p>\n Access the research here: <\/strong><\/span><\/span>Chronic Treatment with 50 mg\/kg Cannabidiol Improves Cognition and Moderately Reduces A\u03b240 Levels in 12-Month-Old Male A\u03b2PPswe\/PS1\u0394E9 Transgenic Mice<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n Overall, CBD and THC can act to recover from memory decline even in more advanced and severe stages of the disease.<\/strong>This is shown by a 2016 <\/span><\/span>study<\/span><\/span><\/a> in which the authors argue that cognitive recovery in animal models occurred through the modulation of glutamatergic and GABAergic neurotransmission – in AD progression, there is a loss of GABAergic neurons.\u00a0<\/p>\n \u00a0<\/p>\n Read <\/strong><\/span><\/span>Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n The main current therapeutic arsenal for AD is acetylcholinesterase (AChE) inhibitor drugs, which increase the availability of acetylcholine in the synaptic cleft, alleviate AD symptoms, and reduce the rate of progression of cognitive decline. However, most patients are not sensitive to AChE inhibitors and do not demonstrate satisfactory clinical results with these drugs<\/strong>.<\/sup>\u00a0<\/p>\n \u00a0<\/p>\n Learn more about it in this article <\/strong><\/span><\/span>Alzheimer\u2019s Disease: Etiological Hypotheses and Treatment Perspectives<\/strong><\/span><\/span><\/a><\/span><\/p>\n \u00a0<\/p>\n Furthermore, despite the increased availability of ACh showing improvements in AD symptoms, AChE inhibitors are not selective, which makes frequent a myriad of dose-dependent adverse effects, such as gastrointestinal disorders (diarrhea, nausea, vomiting, reduction appetite) and bronchoconstriction.<\/p>\n In this scenario, cannabinoid derivatives prove <\/span><\/span>to be an interesting therapeutic tool<\/strong><\/span><\/span><\/a>as they act as neuroprotectors, neuroantioxidants and neuroanti-inflammatory drugs, and at the same time, they present a low profile of toxicity and adverse effects.\u00a0<\/p>\n \u00a0<\/p>\n About this, read the article Canabinoides como uma nova op\u00e7\u00e3o terap\u00eautica nas doen\u00e7as de Parkinson e Alzheimer: uma revis\u00e3o de literatura.<\/span><\/a> e confira nosso Guia de como dosar derivados canabinoides.<\/strong><\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n The main phytocannabinoids CBD and THC demonstrate the ability to reduce the formation and deposition of \u03b2 amyloid plaques, reduce tau protein hyperphosphorylation, modulate glutamatergic and GABAergic neurotransmission, protect neuronal toxicity and prevent degeneration of the hippocampus and cerebral cortex.\u00a0<\/p>\n \u00a0<\/p>\n If you are interested in learning more about safe and assertive prescriptions for cannabinoid derivatives, be sure to follow our blog. Also check out the <\/span><\/span>WeCann Academy<\/span><\/span><\/a>\u2019s international certification, which aims to prepare physicians to safely and effectively incorporate Endocannabinoid Medicine into their medical practice.\u00a0<\/p>\n \u00a0<\/p>\n References<\/strong><\/p>\n Aso E, Andr\u00e9s-Benito P, Ferrer I. <\/span><\/span>Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model<\/span><\/span><\/a>. J Alzheimers Dis. 2016 Oct 4;54(3):903-912. doi: 10.3233\/JAD-160533. PMID: 27567873. <\/p>\n ASSOCIA\u00c7\u00c3O BRASILEIRA DE ALZHEIMER. Doen\u00e7a de Alzheimer. Dispon\u00edvel\u00a0em: <\/span><\/span>http:\/\/abraz.org.br\/web\/<\/span><\/span><\/a>.<\/span><\/span> Acesso em: 09 jun. 2021.\u00a0<\/p>\n B.M. McGleenon, K.B. Dynan, A.P. Passmore, <\/span><\/span>Acetylcholinesterase inhibitors inAlzheimer\u2019s disease<\/span><\/span><\/a>, Br. J. Clin. Pharmacol. 48 (4) (1999) 471\u2013480\u00a0<\/p>\n Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. <\/span><\/span>Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice<\/span><\/span><\/a>. J Alzheimers Dis. 2014;42(4):1383-96. doi: 10.3233\/JAD-140921. PMID: 25024347.<\/p>\n Del Cerro P, Alqu\u00e9zar C, Bartolom\u00e9 F, Gonz\u00e1lez-Naranjo P, P\u00e9rez C, Carro E, P\u00e1ez JA, Campillo NE, Mart\u00edn-Requero \u00c1. <\/span><\/span>Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer\u2019s Disease<\/span><\/span><\/a>. CNS Drugs. 2018 Jun;32(6):579-591. doi: 10.1007\/s40263-018-0515-7. PMID: 29736745.<\/p>\n Falco, Anna De et al. <\/span><\/span>DOEN\u00c7A DE ALZHEIMER: HIP\u00d3TESES ETIOL\u00d3GICAS E PERSPECTIVAS DE TRATAMENTO<\/span><\/span><\/a>. Qu\u00edmica Nova [online]. 2016, v. 39, n. 1 [Acessado 9 Junho 2021] , pp. 63-80.\u00a0<\/p>\n FILHO, M. F. A. C. et al. <\/span><\/span>Canabinoides como uma nova op\u00e7\u00e3o terap\u00eautica nas<\/span><\/span><\/a>\u00a0<\/span>doen\u00e7as de Parkinson e de Alzheimer: uma revis\u00e3o de literatura<\/span><\/span><\/a>. Revista Brasileira de Neurologia. Curitiba, v. 55, n. 2, p.17-32, abr. 2019.\u00a0<\/p>\n Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, Baruch Y. <\/span><\/span>Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study<\/span><\/span><\/a>.<\/span><\/span> J Alzheimers Dis. 2016;51(1):15-9. doi: 10.3233\/JAD-150915. PMID: 26757043.<\/p>\n SOUSA, I. G. D; MARQUES N. M. <\/span><\/span>Descobertas sobre o uso de cannabis na<\/span><\/span><\/a>doen\u00e7a de alzheimer: uma revis\u00e3o da literatura<\/span><\/span><\/a>. In: CONGRESSO INTERNACIONAL DE ENVELHECIMENTO HUMANO, 6, 2019, Campina Grande. Anais eletr\u00f4nicos\u2026Campina Grande, 2019.\u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":" \u00a0 Alzheimer\u2019s Disease (AD) is the most common neurodegenerative disease in the world and the main cause of functional dependence, institutionalization and death among the elderly population in Brazil.\u00a0 With the increase in life expectancy, it is estimated that every 33 seconds there is a new case of the disease. According to the World Health […]<\/p>\n","protected":false},"author":2,"featured_media":1378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sem-categoria"],"acf":[],"_links":{"self":[{"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/posts\/1536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/comments?post=1536"}],"version-history":[{"count":4,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/posts\/1536\/revisions"}],"predecessor-version":[{"id":3546,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/posts\/1536\/revisions\/3546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/media\/1378"}],"wp:attachment":[{"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/media?parent=1536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/categories?post=1536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wecann.academy\/en\/wp-json\/wp\/v2\/tags?post=1536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What is already known about medicinal Cannabis use in Alzheimer\u2019s\u00a0<\/h2>\n
Why can medical Cannabis be an important ally in the treatment of Alzheimer\u2019s Dementia?<\/h2>\n
![\"dosar](\"https:\/\/wecann.academy\/wp-content\/uploads\/2021\/07\/CR07_CTAblog_Capa.png\" "\\"\\"")
<\/p>\n
\n